BridgeBio's Calcilytix Sees POC For Encaleret And Options To Discuss With FDA
Company Presents Early Phase II Data At ENDO
Calcilytix chief medical officer Jonathan Fox talked to Scrip about the development plans for encaleret for the rare form of hypoparathyroidism.
You may also be interested in...
Since raising $135m in 2017 to address rare, monogenic diseases, BridgeBio has launched or purchased 17 companies and built a pipeline of 30-plus candidates. Scrip checked in as the company nears commercialization.
The German drug maker is spending CHF450m to acquire T3, which is focused on developing live bacteria to treat cancers.
The drug maker will spend up to $610m to acquire Caraway, with a lead product candidate targeting TRPML1, a pathway implicated in a number of neurodegenerative diseases.